A New Link Between Metabolism, Exercise, and Cancer Care
A fascinating new study has uncovered something highly relevant to prostate cancer patients and their care teams: a commonly used medication—metformin—may mimic some of the metabolic benefits of exercise by increasing a molecule called Lac-Phe.
Why does this matter?
Because both exercise and weight control are strongly linked to improved cancer outcomes, yet many patients—especially those undergoing treatment—struggle to maintain consistent physical activity. This research provides a potential biological bridge between exercise physiology and cancer therapeutics.
What Is Lac-Phe—and Why Should You Care?
Lac-Phe (N-lactoyl-phenylalanine) is a metabolite that:
- Is naturally produced during exercise
- Helps regulate appetite and body weight
- Is associated with anti-obesity effects
This study shows that metformin significantly increases Lac-Phe levels in prostate cancer patients, reaching levels similar to those seen after strenuous exercise.
This is a key insight:
👉 We may be able to pharmacologically “replicate” some benefits of exercise at the molecular level.
Why This Is Critical for Prostate Cancer Patients
1. Hormone Therapy Causes Weight Gain
Many prostate cancer patients receive androgen deprivation therapy (ADT), which:
- Promotes weight gain
- Increases risk of metabolic syndrome
- Raises risk of cardiovascular complications
This study showed that patients taking metformin:
- Had better weight control
- Were less likely to gain weight during therapy
2. Obesity Worsens Cancer Outcomes
Obesity is not just a side effect—it is a driver of worse outcomes, including:
- Increased risk of recurrence
- Higher cancer-specific mortality
- Reduced treatment effectiveness
Anything that improves metabolic health becomes clinically meaningful.
3. Exercise Remains Foundational—but Not Always Feasible
We know from multiple trials that:
- Exercise improves survival and quality of life
- It enhances treatment tolerance
But in real-world oncology:
- Many patients are fatigued
- Some are frail or elderly
- Others face treatment-related limitations
This is where the study becomes particularly important.
A Potential “Exercise Mimetic” Strategy
The most exciting implication:
👉 Metformin may act as a partial “exercise mimetic” by increasing Lac-Phe.
In this study:
- Lac-Phe levels increased consistently across all disease stages
- This occurred independent of BMI, treatment status, or cancer stage
- Levels were comparable to those seen with vigorous exercise
This suggests a shared biological pathway between:
- Exercise
- Weight control
- Metabolic health
- Cancer outcomes
Important Caveats for Clinicians
While promising, this is not a replacement for exercise.
Key points for providers:
- Lac-Phe did NOT predict tumor response in this study
- Metformin’s anticancer effects remain inconclusive
- This is an early mechanistic insight, not a definitive treatment strategy
However, it does provide:
✔ A biomarker (Lac-Phe) for metabolic response
✔ A potential target for future therapies
✔ A rationale for combining pharmacology + lifestyle interventions
Clinical Takeaways for Oncology Teams
For cancer providers, this study reinforces several key principles:
1. Metabolic Health Is Oncology Care
Managing weight, insulin sensitivity, and inflammation is not optional—it is core cancer care.
2. Consider Metformin Strategically
In appropriate patients (especially those with metabolic dysfunction), metformin may:
- Improve weight control
- Favorably impact metabolic pathways linked to cancer progression
3. Measure What Matters
Future care models may include:
- Biomarkers like Lac-Phe
- Body composition tracking
- Personalized exercise + metabolic plans
What This Means for Patients
If you are a prostate cancer patient:
- Exercise remains one of the most powerful tools you have
- Even modest activity can improve outcomes
- Medications like metformin may support—but not replace—healthy lifestyle changes
👉 The goal is not either/or
👉 The goal is both/and
The Bigger Picture: A Turning Point in Exercise Oncology
This study helps move the field forward by answering a critical question:
How does exercise actually work at the molecular level in cancer?
By identifying Lac-Phe as a shared mediator, it:
- Strengthens the biological case for exercise as medicine
- Opens the door to new therapeutic strategies
- Bridges lifestyle medicine and oncology
CancerFitness.org Call to Action
It’s time to elevate exercise and metabolic health to standard components of cancer care.
For providers:
- Integrate exercise oncology programs
- Address weight and metabolic risk early
For patients:
- Start where you are
- Move consistently
- Ask your care team about exercise and metabolic strategies
Bottom Line
This study reinforces a powerful concept:
👉 The biology of exercise can now be measured—and potentially amplified.
And that brings us one step closer to making exercise oncology a true standard of care.
Reference: The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients. Marijo Bilusic, Durga Prasad Gannamedi, Bhipasha Challu, Shomita Ferdous, et al. EMBO Molecular Medicine https://doi.org/10.1038/s44321-026-00408-6
